Free Trial
TSE:HBP

Helix BioPharma Q3 2026 Earnings Results & Report

Helix BioPharma logo
C$0.96 0.00 (0.00%)
As of 10/13/2026 03:46 PM Eastern

Helix BioPharma reported Q3 2026 earnings on June 12, 2026. The company reported EPS of -C$0.01.

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
After Market Closes

Helix BioPharma EPS Results

Actual EPS
-C$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Helix BioPharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Helix BioPharma Q3 2026 Earnings FAQ

Helix BioPharma (TSE:HBP) reported earnings of -C$0.01 per share for Q3 2026. The report was announced on Friday, June 12, 2026.

Helix BioPharma Earnings Headlines

Off-market insider selling at Helix BioPharma (HBP)
The Midwestern Disruptor Big Pharma Doesn’t Want You to Know About
A little-known Midwestern firm sits at the center of what the Wall Street Journal calls medicine's biggest moment since antibiotics. It does not invent drugs or hold blockbuster patents. McKinsey calls the shift a game changer, and the International Journal of Surgery describes it as a revolutionary path forward. Yet this company remains largely overlooked by investors. See the full research on this emerging healthcare story now.tc pixel
HBP.TO - | Stock Price & Latest News | Reuters
Kurs Helix BioPharma Corp.
See More Helix BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Helix BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Helix BioPharma and other key companies, straight to your email.

About Helix BioPharma

Helix BioPharma (TSE:HBP) is an oncology company that innovates from strength to bring near-term solutions for today's hardest-to-treat cancers. The Company's pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today's front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix's next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery. The Company also advances two pre-IND candidates: (i) LEUMUNA¿, an oral immune checkpoint modulator aimed at achieving durable remission in post-transplant leukemia relapse, and (ii) GEMCEDA¿, a first-in-class oral gemcitabine prodrug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers.

View Helix BioPharma Profile